Patient enrollment into the REQUEST registry study is completed and the final results have been accepted for presentation in the Late-Breaking Clinical Trial session at the AATS Annual Meeting taking place in San Diego between April 28th and May 1st, 2018.
The objective for the REQUEST study is to document how often the combination of high-resolution ultrasound imaging and transit time flow measurements (TTFM) performed with Medistim’s VeriQC or MiraQ devices will change the surgical procedure. The surgical coronary artery bypass grafting (CABG) protocol includes ultrasound scanning of the aorta, conduit, target coronary vessel and anastomosis, as well as TTFM graft assessment.
More than 1,000 CABG patients were included in this prospective multicenter registry study between February 2015 and December 2017. Seven leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford participated.
Preliminary results from 776 patients showed that 26% of the patient population had one or more surgical changes made to the procedure based on imaging and flow data. Now, the final results from more than 1,000 patients have been accepted for presentation in the Late-Breaking Clinical Trial session at the 98th Annual Meeting for American Association for Thoracic Surgery (AATS) taking place in San Diego between April 28 – May 1, 2018.
“Medistim is very excited about reaching this important milestone”, says Medistim President and CEO, Kari E. Krogstad. “For the first time, a large amount of information is available documenting the number and type of surgical changes resulting from the combined use of Medistim TTFM and high-resolution ultrasound imaging. We believe that the REQUEST study results may provide new insights that could impact surgical insight and clinical outcomes practice going forward.”